APA (7th ed.) Citation

D, I., R, F., NS, J., P, G., J, G., C, L., . . . K, T. (2021). Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.), 73(10), 1835. https://doi.org/10.1002/art.41811

Chicago Style (17th ed.) Citation

D, Isenberg, et al. "Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial." Arthritis & Rheumatology (Hoboken, N.J.) 73, no. 10 (2021): 1835. https://doi.org/10.1002/art.41811.

MLA (9th ed.) Citation

D, Isenberg, et al. "Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial." Arthritis & Rheumatology (Hoboken, N.J.), vol. 73, no. 10, 2021, p. 1835, https://doi.org/10.1002/art.41811.